Jennison Associates LLC decreased its holdings in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 0.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,024,691 shares of the biotechnology company’s stock after selling 3,977 shares during the quarter. Jennison Associates LLC’s holdings in Audentes Therapeutics were worth $21,846,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of BOLD. Victory Capital Management Inc. boosted its stake in Audentes Therapeutics by 13.3% in the fourth quarter. Victory Capital Management Inc. now owns 862,561 shares of the biotechnology company’s stock valued at $18,390,000 after acquiring an additional 101,200 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Audentes Therapeutics by 8.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 13,184 shares of the biotechnology company’s stock worth $281,000 after buying an additional 1,053 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Audentes Therapeutics by 38.8% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 13,669 shares of the biotechnology company’s stock worth $291,000 after buying an additional 3,819 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Audentes Therapeutics by 56.3% in the fourth quarter. Rhumbline Advisers now owns 46,150 shares of the biotechnology company’s stock worth $984,000 after buying an additional 16,632 shares during the last quarter. Finally, Fosun International Ltd purchased a new position in shares of Audentes Therapeutics in the fourth quarter worth $546,000. 89.11% of the stock is owned by hedge funds and other institutional investors.
Shares of Audentes Therapeutics stock opened at $25.74 on Friday. Audentes Therapeutics Inc has a 1 year low of $17.95 and a 1 year high of $46.18. The firm has a market cap of $1.11 billion, a P/E ratio of -7.57 and a beta of 1.79.
In related news, Director Louis G. Lange sold 32,000 shares of the firm’s stock in a transaction on Monday, December 24th. The shares were sold at an average price of $18.62, for a total transaction of $595,840.00. Following the completion of the transaction, the director now owns 325,799 shares of the company’s stock, valued at $6,066,377.38. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 6.60% of the company’s stock.
A number of research firms have issued reports on BOLD. BidaskClub cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 8th. Zacks Investment Research raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a report on Tuesday, January 8th. Cowen reaffirmed a “buy” rating on shares of Audentes Therapeutics in a report on Thursday, January 31st. ValuEngine cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 12th. Finally, William Blair reaffirmed a “hold” rating on shares of Audentes Therapeutics in a report on Thursday, January 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $31.79.
COPYRIGHT VIOLATION WARNING: This story was first reported by Zolmax and is the property of of Zolmax. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://zolmax.com/investing/jennison-associates-llc-sells-3977-shares-of-audentes-therapeutics-inc-bold/2918801.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Further Reading: Trading Strategy
Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.